S'abonner

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial - 30/03/21

Doi : 10.1016/S1470-2045(21)00004-8 
Joaquim Bellmunt, MD a, , Maha Hussain, ProfMD b, Jürgen E Gschwend, ProfMD c, Peter Albers, ProfMD d, Stephane Oudard, ProfMD e, Daniel Castellano, MD f, Siamak Daneshmand, MD g, Hiroyuki Nishiyama, ProfMD h, Martin Majchrowicz, MPH i, Viraj Degaonkar, PharmD i, Yi Shi, PhD i, Sanjeev Mariathasan, PhD i, Petros Grivas, MD j, k, l, Alexandra Drakaki, MD m, Peter H O’Donnell, MD n, Jonathan E Rosenberg, ProfMD o, p, Daniel M Geynisman, MD q, Daniel P Petrylak, ProfMD r, Jean Hoffman-Censits, MD s, Jens Bedke, ProfMD t, Arash Rezazadeh Kalebasty, MD u, Yousef Zakharia, MD v, Michiel S van der Heijden, MD w, Cora N Sternberg, ProfMD x, Nicole N Davarpanah, MD i, Thomas Powles, ProfMD y
for the

IMvigor010 Study Group

  Investigators in the IMvigor010 Study Group are listed in the appendix

a Beth Israel Deaconess Medical Center and PSMAR-IMIM Lab, Harvard Medical School, Boston, MA, USA 
b Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA 
c Department of Urology, Rechts der Isar Hospital, Technical University of Munich, Munich, Germany 
d Department of Urology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany 
e Georges Pompidou European Hospital, University of Paris, Paris, France 
f Medical Oncology Department University Hospital 12 de Octubre, CIBER-ONC, Madrid, Spain 
g Department of Urology, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA 
h Department of Urology, Faculty of Medicine University of Tsukuba, Ibaraki, Japan 
i Genentech, South San Francisco, CA, USA 
j Division of Medical Oncology, University of Washington, Seattle, WA, USA 
k Division of Medical Oncology, Seattle Cancer Care Alliance, Seattle, WA, USA 
l Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 
m Division of Hematology/Oncology, University of California, Los Angeles, Los Angeles, CA, USA 
n Department of Medicine, University of Chicago, Chicago, IL, USA 
o Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA 
p Department of Medical Oncology, Weill Cornell Medical College, New York, NY, USA 
q Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA 
r Department of Urology, Yale Cancer Center, New Haven, CT, USA 
s Department of Medical Oncology and Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA 
t Department of Urology, University of Tübingen, Tübingen, Germany 
u Department of Hematology/Oncology, University of California, Irvine, Irvine, CA, USA 
v Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA 
w Netherlands Cancer Institute, Amsterdam, Netherlands 
x Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY, USA 
y Barts Cancer Institute, Queen Mary University of London, St Bartholomew’s Hospital, London, UK 

* Correspondence to: Dr Joaquim Bellmunt, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA Beth Israel Deaconess Medical Center Harvard Medical School Boston MA 02215 USA

Summary

Background

Despite standard curative-intent treatment with neoadjuvant cisplatin-based chemotherapy, followed by radical surgery in eligible patients, muscle-invasive urothelial carcinoma has a high recurrence rate and no level 1 evidence for adjuvant therapy. We aimed to evaluate atezolizumab as adjuvant therapy in patients with high-risk muscle-invasive urothelial carcinoma.

Method

In the IMvigor010 study, a multicentre, open-label, randomised, phase 3 trial done in 192 hospitals, academic centres, and community oncology practices across 24 countries or regions, patients aged 18 years and older with histologically confirmed muscle-invasive urothelial carcinoma and an Eastern Cooperative Oncology Group performance status of 0, 1, or 2 were enrolled within 14 weeks after radical cystectomy or nephroureterectomy with lymph node dissection. Patients had ypT2–4a or ypN+ tumours following neoadjuvant chemotherapy or pT3–4a or pN+ tumours if no neoadjuvant chemotherapy was received. Patients not treated with neoadjuvant chemotherapy must have been ineligible for or declined cisplatin-based adjuvant chemotherapy. No post-surgical radiotherapy or previous adjuvant chemotherapy was allowed. Patients were randomly assigned (1:1) using a permuted block (block size of four) method and interactive voice-web response system to receive 1200 mg atezolizumab given intravenously every 3 weeks for 16 cycles or up to 1 year, whichever occurred first, or to observation. Randomisation was stratified by previous neoadjuvant chemotherapy use, number of lymph nodes resected, pathological nodal status, tumour stage, and PD-L1 expression on tumour-infiltrating immune cells. The primary endpoint was disease-free survival in the intention-to-treat population. Safety was assessed in patients who either received at least one dose of atezolizumab or had at least one post-baseline safety assessment. This trial is registered with ClinicalTrials.gov, NCT02450331, and is ongoing but not recruiting patients.

Findings

Between Oct 5, 2015, and July 30, 2018, we enrolled 809 patients, of whom 406 were assigned to the atezolizumab group and 403 were assigned to the observation group. Median follow-up was 21·9 months (IQR 13·2–29·8). Median disease-free survival was 19·4 months (95% CI 15·9–24·8) with atezolizumab and 16·6 months (11·2–24·8) with observation (stratified hazard ratio 0·89 [95% CI 0·74–1·08]; p=0·24). The most common grade 3 or 4 adverse events were urinary tract infection (31 [8%] of 390 patients in the atezolizumab group vs 20 [5%] of 397 patients in the observation group), pyelonephritis (12 [3%]) vs 14 [4%]), and anaemia (eight [2%] vs seven [2%]). Serious adverse events occurred in 122 (31%) patients who received atezolizumab and 71 (18%) who underwent observation. 63 (16%) patients who received atezolizumab had a treatment-related grade 3 or 4 adverse event. One treatment-related death, due to acute respiratory distress syndrome, occurred in the atezolizumab group.

Interpretation

To our knowledge, IMvigor010 is the largest, first-completed phase 3 adjuvant study to evaluate the role of a checkpoint inhibitor in muscle-invasive urothelial carcinoma. The trial did not meet its primary endpoint of improved disease-free survival in the atezolizumab group over observation. Atezolizumab was generally tolerable, with no new safety signals; however, higher frequencies of adverse events leading to discontinuation were reported than in metastatic urothelial carcinoma studies. These data do not support the use of adjuvant checkpoint inhibitor therapy in the setting evaluated in IMvigor010 at this time.

Funding

F Hoffmann-La Roche/Genentech.

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 22 - N° 4

P. 525-537 - avril 2021 Retour au numéro
Article précédent Article précédent
  • Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
  • John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, Laura Maria Fogliatto, Iara Goncalves, Jose S R de Oliveira, Valeria Buccheri, Guilherme F Perini, Neta Goldschmidt, Iryna Kriachok, Michael Dickinson, Mieczyslaw Komarnicki, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Ying Zhu, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, KEYNOTE-204 investigators
| Article suivant Article suivant
  • MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
  • Richard Pötter, Kari Tanderup, Maximilian Paul Schmid, Ina Jürgenliemk-Schulz, Christine Haie-Meder, Lars Ulrik Fokdal, Alina Emiliana Sturdza, Peter Hoskin, Umesh Mahantshetty, Barbara Segedin, Kjersti Bruheim, Fleur Huang, Bhavana Rai, Rachel Cooper, Elzbieta van der Steen-Banasik, Erik Van Limbergen, Bradley Rumwell Pieters, Li-Tee Tan, Remi Abubakar Nout, Astrid Agatha Catharina De Leeuw, Robin Ristl, Primoz Petric, Nicole Nesvacil, Kathrin Kirchheiner, Christian Kirisits, Jacob Christian Lindegaard, EMBRACE Collaborative Group, Cyrus Chargari, Isabelle Dumas, Gerry Lowe, Jamema Swamidas, Robert Hudej, Taran Paulsen Hellebust, Geetha Menon, Arun S. Oinam, Peter Bownes, Melissa Christiaens, Marisol De Brabandere, Hilde Janssen, Bernard Oosterveld, Kees Koedooder, Anne Beate Langeland Marthinsen, Marit Sundset, Diane Whitney, Martijn Ketelaars, Ludy C.H.W. Lutgens, Brigitte Reinniers, Itxa Mora, Elena Villafranca, Gergely Antal, Janaki Hadjiev, Francois Bachand, Deidre Batchelar, Beth Erickson, Jason Rownd, Geraldine Jacobson, Yusung Kim, Maarit Anttila, Jan-Erik Palmgren, Jusheng An, Marianne Sanggaard Assenholt, Susovan Banerjee, Sören Bentzen, Thomas Berger, Pittaya Dankulchai, Tamara Diendorfer, Ian Dilworth, Johannes Dimopoulos, Elke Dörr, Stefan Ecker, Mario Federico, Elena Fidarova, Israel Fortin, Petra Georg, Joanna Gora, Neamat Hegazy, Noha Jastaniyah, Nina Boje Kibsgaard Jensen, Thomas Liederer, Katarina Majercakova, Dragan Misimovic, Laura Motisi, Dina Najjari Jamal, Karen Nkiwane, Anders Schwartz-Vittrup, Monica Serban, Stephanie Smet, Sofia Spampinato, Petra Trnkova, Margit Valgma, Henrike Westerveld, Joyce Siu Yu Wong, Kenji Yoshida

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.